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Abstract
GATA4 and GATA6 are central cardiac transcriptional regulators. The postnatal, stage-spe-
cific function of the cardiac transcription factors GATA4 and GATA6 have not been evaluat-
ed. In part, this is because current Cre-loxP approaches to cardiac gene inactivation require
time consuming and costly breeding of Cre-expressing and “floxed”mouse lines, often with
limited control of the extent or timing of gene inactivation. We investigated the stage-specific
functions of GATA4 and GATA6 in the postnatal heart by using adeno-associated virus se-
rotype 9 to control the timing and extent of gene inactivation by Cre. Systemic delivery of re-
combinant, adeno-associated virus 9 (AAV9) expressing Cre from the cardiac specific
Tnnt2 promoter was well tolerated and selectively and efficiently recombined floxed target
genes in cardiomyocytes. AAV9:Tnnt2-Cre efficiently inactivated Gata4 andGata6. Neona-
talGata4/6 inactivation caused severe, rapidly lethal systolic heart failure. In contrast,
Gata4/6 inactivation in adult heart caused only mild systolic dysfunction but severe diastolic
dysfunction. Reducing the dose of AAV9:Tnnt2-Cre generated mosaics in which scattered
cardiomyocytes lackedGata4/6. This mosaic knockout revealed thatGata4/6 are required
cell autonomously for physiological cardiomyocyte growth. Our results define novel roles of
GATA4 and GATA6 in the neonatal and adult heart. Furthermore, our data demonstrate that
evaluation of gene function hinges on controlling the timing and extent of gene inactivation.
AAV9:Tnnt2-Cre is a powerful tool for controlling these parameters.
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Introduction
GATA4 and GATA6 are critical cardiac transcription factors with partial functional redundan-
cy [1,2]. Previous gene inactivation studies have interrogated the function of GATA4 and
GATA6 using several different cardiac Cre alleles. Inactivation in cardiac progenitors or early
cardiomyocytes using Nkx2-5Cre showed that GATA4 is required for cardiomyocyte prolifera-
tion and embryonic survival [3]. Later fetal inactivation of either GATA4 or GATA6 with
Myh6-Cre (also known as MHCα-Cre) permitted embryonic survival [4,5]. These mutant
mice developed progressive dilated cardiomyopathy with severe systolic dysfunction and died
in adulthood. Furthermore, these mice had attenuated cardiomyocyte hypertrophy in response
to pressure overload, indicating that GATA4 and GATA6 are required for this pathological
growth response. Surprisingly, inactivation of both Gata4 and Gata6 with Myh6-Cre was com-
patible with embryonic survival, and suggested an additive effect of combined inactivation of
both GATA4 and GATA6 [2,4]. However, the extent to which the adult phenotypes reflect de-
velopmental roles of GATA4 or GATA6 or their function in the adult heart remain uncertain.
Genetic loss of function is a commonly used strategy to decipher essential gene functions in
vivo. In cardiac biology, floxed genes are inactivated most commonly by constitutive Cre alleles
active in the fetal heart. While this strategy has been highly productive, it can lead to experi-
mental hurdles (e.g., inability to analyze gene function due to premature death). Moreover, the
interpretation of experiments can be confounded by the impact of developmental changes on
later stage phenotypes, and by secondary consequences of organ-wide gene inactivation. Re-
cently, “inducible Cre”-based genetic inactivation strategies have been increasingly used to
achieve temporal control of gene inactivation. Most often this is achieved using Cre fused to ta-
moxifen-activated variants of the estrogen hormone binding domain, such as CreERT2 or Mer-
CreMer [6,7]. However, incomplete gene inactivation and toxicity related to the combination
of these fusion genes and tamoxifen, including cardiac fibrosis and left ventricular dysfunction,
are additional difficulties that must be addressed when using these inducible Cre experimental
models [8–11].
Here, we use adeno-associated virus (AAV) as an alternative approach to achieve control
the timing and extent of Gata4 and Gata6 cardiac inactivation. AAV is a highly efficient, non-
pathogenic cardiac gene transfer vehicle that elicits little significant immune response [12].
AAV serotype 9 (AAV9) efficiently delivers its cargo to post-mitotic cells including cardiomyo-
cytes [13], and we show that AAV9-mediated Cre delivery is a simple and effective means to
control the timing and extent of cardiomyocyte gene inactivation. By controlling the extent
and timing of gene inactivation with AAV9 delivery of Cre, we uncovered novel roles of Gata4
and Gata6 in the growth, contractile maturation, and diastolic function of the postnatal heart.
These phenotypes differ from those that result from fetal knockout of Gata4/6 [4], highlighting
how the timing and extent of gene inactivation critically impact the interpretation of experi-
mental results.
Materials and Methods
Adeno-associated Virus
AAV9:Tnnt2-Cre and AAV:Tnnt2-Luc were constructed by placing codon-optimized Cre [14]
or Luciferase into an ITR-containing AAV plasmid (Penn Vector Core P1967) harboring the
chicken cardiac TNT promoter. AAV constructs were propagated in Stbl2 competent cells
(Life Technologies; Cat. # 10268–019), and their integrity was validated by restriction digestion
and DNA sequencing. AAV9 was packaged at the Viral Vector Core of the Gene Therapy Cen-
ter, University of Massachusetts Medical School. Viral titer was determined by quantitative
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PCR. AAV:Tnnt2-Cre contained IRES-TdTomato, although the level of TdTomato expression
was not detectable by microscopy. Aliquots were stored at -80°C prior to use.
Mice
All experiments involving animals were approved by the Boston Children’s Hospital Animal
Care and Use Committee. Gata4 [15], Gata6 (JAX# 008196) [16], and Rosa26mTmG/mTmG [17]
mice were obtained from Jackson Labs. Mice were injected under light isoflurane anesthesia at
a dose of 1x1011 VP/gram body weight by injection (pups). Pups and adults were injected intra-
peritoneally and intravascularly, respectively.
Physiological measurements
Echocardiography was performed under light anesthesia (0.5%-1.5% isoflurane mixed with ox-
ygen) on a heated animal platform using the Vevo 2100 imaging system with MS550D
(40MHz) transducer (VisualSonics Inc.). Mice were monitored for core temperature, heart rate
and level of anesthesia. Ventricular volumes, wall thickness and function (ejection fraction or
shortening fraction) were determined fromM-mode cine loops taken in the parasternal short
and long axis planes. B-mode cine loops were also acquired and analyzed using Vevostrain
analysis software (VisualSonics Inc.). Mitral valve inflow gradient was acquired using Doppler
interrogation at the level of the valve annulus from a 4-chamber view.
Closed chest cardiac catheterization was performed under light anesthesia (1–3% isoflurane
mixed with oxygen) using a 1.2F SciSense ADVantage pressure catheter and accompanying sys-
tem for measuring pressure-volume loops. Access was obtained through cannulation of the right
carotid artery under local dissection, and the catheter was advanced across the aortic valve into
the left ventricular cavity. Further data analysis was done using Labchart v.8 software.
Histology
Myocardial cryostat sections (10 μm) were immunostained using antibodies listed in Table 1.
Sections were mounted with Vectashield with DAPI and imaged using an Olympus FV1000
confocal microscope. Other sections were stained with picro-sirius red and fast green and im-
aged with a Nikon SMZ1000 dissecting microscope.
Gene expression
Western blot analysis of mouse neonatal heart homogenates was performed using antibodies
indicated in Table 1.
For quantitation of RNA expression, total RNA was extracted from snap-frozen ventricular
myocardial tissue. RNA was purified using an RNeasy Mini kit (Qiagen, Cat. # 74104). cDNA
was made from total RNA using Superscript III first-strand synthesis system (Invitrogen; Cat.
Table 1. Antibodies used in this study.
Gene Vendor Cat No Dilution Purpose
GATA4 Santa Cruz Sc-9053 1:1,000 WB
GATA6 Cell Signaling 4253S 1:1,000 WB
GAPDH Fitzgerald Ind. 10R-G109a 1:20,000 WB
TNNI3 Abcam Ab56357 1:250 IF
WB, western blot; IF, immunoﬂuorescent staining.
doi:10.1371/journal.pone.0128105.t001
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# 18080–051). qPCR was performed on a Bio-Rad CFX96 real-time system using Fast SYBR
Green Master mix (Applied Biosystems, Cat. # 4385612) using primers indicated in Table 2.
Cardiomyocyte dissociation
Neonatal hearts were dissociated using the Miltenyi neonatal heart dissociation kit, and cardio-
myocytes were purified by magnetic cell sorting (Miltenyi Biotec #130-098-373). Fluorescence-
activated cell sorting (FACS) was performed on a BD FACSAria II. Adult hearts were dissociat-
ed by retrograde collagenase perfusion [18].
Cell size measurement
In cryosections, cell cross-sectional area was measured in ImageJ by manually outlining cardio-
myocytes based on the membrane-localized GFP or RFP signal. Adult hearts were dissociated
by retrograde collagenase perfusion and cardiomyocytes were isolated by differential centrifu-
gation as described [18]. Random fields of cardiomyocytes were imaged and the projected area
was measured by manually outlining cardiomyocytes in ImageJ. Cells were grouped into those
with and without GFP expression.
Statistics
All results are presented as mean ± SEM. Statistical analyses were performed in Microsoft
Excel and GraphPad Prism (v6) using an unpaired t-test (qPCR and echocardiography data)
and the Mann-Whitney U test (cardiac catheterization and cell size data). A p-value of< 0.05
was considered significant.
Results
Cardiomyocyte-specific recombination of floxed genes by
AAV9-Tnnt2-Cre
We generated AAV9 containing the cardiomyocyte-selective Tnnt2 promoter driving mamma-
lian codon optimized Cre (AAV9:Tnnt2-Cre). We intraperitoneally injected the virus into
neonatal Rosa26mTmG Cre-reporter mice, in which Cre recombination activates membrane-lo-
calized green fluorescent protein (mGFP) and inactivates red fluorescent protein (mRFP).
Table 2. Primers used in this study.
Gene Sequence
Gata4-F GCCGAGGGAGCCGCCTACAC
Gata4-R TGGGGTGTCTTCCAGGGTTGG
Gata6-F AGTTTTCCGGCAGAGCAGTA
Gata6-R GCACTTGGAGCTGTAGGTCA
Myh7-F AAGGGCCTGAATGAGGAGTAGATC
Myh7-R TGCAAAGGCTCCAGGTCTGA
Myh6-F ACATGAAGGAGGAGTTTGGG
Myh6-R GCACTTGGAGCTGTAGGTCA
Nppa-F GGCCATATTGGAGCAAATCCTGTG
Nppa-R CATGACCTCATCTTCTACCGGCAT
GAPDH Life Technologies Taqman assay #4352932E
Primers used in this study are indicated (5’-3’).
doi:10.1371/journal.pone.0128105.t002
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Systemically delivered AAV9:Tnnt2-Cre selectively activated mGFP in the heart (Fig 1A).
Weak GFP fluorescence was detected in the liver, and no GFP was detected in other organs.
Within the heart, we observed robust activation of mGFP in cardiomyocytes (Fig 1B). Cell
counting showed that 95.3 ± 1.3% of cardiomyocytes expressed mGFP (n = 3). We did not de-
tect expression of mGFP in non-cardiomyocytes (arrows, Fig 1B).
AAV9:Tnnt2-Cre was well tolerated in the normal heart. It had little detectable effect on
normal heart function by either echocardiography or invasive hemodynamics (Fig 2A and 2B),
did not induce fibrosis (Fig 2C), and did not alter expression ofMyh6 (also known as MHCα),
cardiac transcription factors Gata4 and Gata6, or cardiac stress markers Nppa (also known as
ANP) andMyh7 (also known as MHCβ; Fig 2D).
Neonatal inactivation of GATA4/6 causes rapidly lethal systolic heart
failure
We used AAV9:Tnnt2-Cre to inactivate floxed alleles of GATA4 and GATA6 in cardiomyo-
cytes. Gata4 and Gata6 are critical cardiac transcription factors with partial functional redun-
dancy in fetal heart development [1]. We treated neonatal GATA4fl/fl::Gata6fl/fl::Rosa26mTmG
Fig 1. Cardiac-selective gene inactivation with AAV9-Tnnt2-Cre. AAV9-Tnnt2-Cre was administered to Rosa26mTmG neonatal mice. Cre recombination
activates GFP expression. (A). Brightfield and GFP fluorescent signal from the indicated organs. skel. m., skeletal muscle. (B). Immunofluorescent staining of
heart cryosections. Green indicates native membrane-localized GFP fluorescence. Cardiomyocytes were stained by TNNI3 (representative examples
indicated by arrowheads). Boxed area in top image is magnified in the bottom image. Arrows indicate non-myocytes. Bar, 100 μm (C, top) and 20 μm (C,
bottom).
doi:10.1371/journal.pone.0128105.g001
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mice with AAV9:Tnnt2-Cre (Fig 3A). AAV9:Tnnt2-Cre rapidly inactivated both Gata4 and
Gata6, as both mRNA and protein were dramatically down-regulated by 5–7 days after virus
administration (Fig 3B and 3C). Control neonates injected with AAV9:Tnnt2-Luc at P1
Fig 2. AAV9:Tnnt2-Cre hadminimal effect on Rosa26mTmG heart functional parameters. (A). Neonatal (left) and adult (right) treatment timelines and
echocardiographic evaluation of heart function. n = 8 per group. *, P<0.05. (B). Closed chest invasive hemodynamics assessment of effect of AAV9:
Tnnt2-Cre on cardiac function. n = 5 per group. (C). Fast green-picrosirius red staining of heart sections. Red staining indicates fibrosis. Bar = 30 μm. (D).
qRTPCR assessment of relative gene expression. n = 3. NS, not significant.
doi:10.1371/journal.pone.0128105.g002
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retained normal ventricular function and experienced no mortality. In contrast, AAV9:
Tnnt2-Cre treatment caused profound, rapidly progressive systolic dysfunction, ventricular di-
latation, and death by 7 days post-injection (Fig 3D and 3E; S1 Table). Rapid death of these
mice was surprising given that mice with fetal Gata4/6 inactivation by Myh7-Cre (also known
as MHCβ-Cre) survived normally through the neonatal period and into adulthood [4], when
they died by ~100 days of age from dilated cardiomyopathy.
Cardiac stress induces a set of genes to revert towards their fetal expression pattern [19,20].
Among these are upregulated genes Nppa andMyh7, and downregulated geneMyh6. GATA4
Fig 3. AAV9:Tnnt2-Cre mediated inactivation ofGata4/6 in neonatal heart. (A). Experimental timeline. AAV9:Tnnt2-Cre or AAV9:Tnnt2-Luc (control)
was administered to P0 pups. Mice were studied daily by echocardiography and tissues were analyzed at P7. (B). qRTPCR assessment ofGata4 andGata6
inactivation in myocardium. (C). Immunoblotting assessment of GATA4 and GATA6 inactivation in myocardium. (D). LV systolic function, measured by
echocardiography. EF, ejection fraction. LVESV, left ventricular end systolic volume. n = 7 per group. *, P<0.05. (E). Gross morphology. Bar = 5 mm. (F).
Expression ofNppa,Myh6, andMyh7, quantified by qRTPCR at P7. n = 3. *, P<0.05.
doi:10.1371/journal.pone.0128105.g003
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has been implicated in the activation of these genes [21–23]. Therefore we investigated the ef-
fect of neonatal Gata4/6 inactivation on expression of these genes. We found that neonatal
Gata4/6 inactivation upregulated both Nppa andMyh7 and downregulatedMyh6 (Fig 3F).
Upregulation of Nppa andMyh7 despite loss of GATA4/6 indicates that their hypertrophy-
driven activation does not require GATA4/6.
Adult GATA4/6 inactivation causes lethal diastolic heart failure
Given the difference in phenotype between fetal and neonatal Gata4/6 inactivation, we asked if
adult inactivation of these genes would also cause a distinct phenotype. We administered
AAV9:Tnnt2-Cre or AAV9:Tnnt2-Luc intravascularly to 6-week old Gata4fl/fl::Gata6fl/fl::
Rosa26mTmG mice (Fig 4A). By 11 weeks of age, cardiac Gata4 and Gata6 transcripts were less
than 10% of control levels (Fig 4B), and western blotting confirmed loss of GATA4 and
GATA6 proteins (Fig 4C). Echocardiography showed that the LV developed mild dysfunction
(EF>60%) and dilatation (Fig 4D and S2 Table). Despite these mild changes in systolic func-
tion and ventricular volume, Cre-treated mice exhibited disproportionate signs and symptoms
of heart failure and required euthanasia by six weeks of age for humanitarian reasons. Echocar-
diography revealed pronounced bi-atrial dilation (Fig 5A), ascites, and pleural and pericardial
effusions (Fig 5B). These abnormalities were not due to possible Gata4/6 inactivation in liver,
since hepatic inactivation of both genes in adults did not cause a significant phenotype [24].
Pulmonary congestion was confirmed by gravimetric analysis of the lungs (Fig 5C), while heart
weight was not significantly changed, consistent with the mild cardiac dilatation.
Fig 4. AAV9:Tnnt2-Cre inactivation ofGata4/6 in adult heart. (A). Experimental timeline. Virus was administred at 6 weeks of age. After weekly
echocardiography, tissue was analyzed at 11 weeks of age. (B).Quantitation ofGata4 andGata6 inactivation in ventricular myocardium by qRTPCR. (C).
Loss of GATA4 and GATA6 protein with AAV9:Tnnt-Cre but not AAV9:Tnnt2-Luc. Ventricular myocardial protein was analyzed by western blotting. (D).Mild
systolic dysfunction following adult stage inactivation of Gata4 and Gata6, as determined by echocardiography. n = 9 (knockout) or 4 (control). *, P<0.05.
doi:10.1371/journal.pone.0128105.g004
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As a result of the overt signs of heart failure and atrial dilation despite relatively preserved
LV systolic function up to the time of death, we hypothesized that diastolic dysfunction was
the underlying hemodynamic mechanism. Consistent with diastolic dysfunction, speckle-
tracking echocardiography showed a significant decline in peak LV diastolic strain (p =
0.028; Fig 5D). Diastolic dysfunction was confirmed by invasive hemodynamics (Fig 5E–5H).
Fig 5. Diastolic dysfunction following Gata4/6 inactivation in adult heart. Studies were performed 5 weeks after AAV delivery. (A-B).
Echocardiographic images were obtained Images show bi-atrial dilatation and intra-atrial thrombus (A) and pericardial, pleural, and abdominal fluid
collections (B). Bar = 1 mm. (C). Heart and lung weights, normalized to tibia length. NS, not significant. *, P<0.05. n = 5 Luc, 7 Cre). (D). Echocardiographic
assessment of diastolic function by peak diastolic strain rate. **, P<0.01. n = 4 Luc, 9 Cre. (E-H). Closed chest invasive hemodynamic assessment of left
ventricular systolic (E,F) and diastolic (G,H) function. n = 5 per group. **, P<0.01. (I). Fast green picrosirius red assessment of ventricular fibrosis. No
significant difference was observed between control and GATA4/6 mutant hearts. Bar = 500 μm.
doi:10.1371/journal.pone.0128105.g005
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AAV9:Tnnt2-Cre-treated mice had lower aortic pressure and reduced maximal +dP/dt, consis-
tent with slightly reduced systolic function (Fig 5E and 5F). There was a profound elevation in
LV end-diastolic pressure and blunted minimum peak -dP/dt, both markers of diastolic dys-
function (Fig 5G and 5H). It is unlikely that fluid accumulations accounted for the observed he-
modynamic derangements, since echocardiography of the catheterized mice showed that only
two of five had ascites and pericardial effusions, and the severity of the hemodynamic abnor-
malities did not correlate with presence of effusions. In summary, the hemodynamic analysis
showed that adult cardiomyocyte inactivation of Gata4/6 cardiomyocyte depressed diastolic
function while only mildly impairing systolic function.
Diastolic dysfunction can be caused by myocardial fibrosis. Picro-sirius red/fast green stain-
ing of adult GATA4/6 knockouts did not reveal a substantial increase in fibrosis (Fig 5I). Thus
impaired diastolic function of Gata4/6 knockout hearts was likely caused by abnormal cardio-
myocyte relaxation.
We measured changes in gene expression in the Gata4/6 adult stage knockouts (Fig 6). As
in the neonatal Gata4/6 loss-of-function experiment,Myh7 and Nppa were highly upregulated
in GATA4/6 knockout hearts, whileMyh6 was highly downregulated, consistent with changes
observed in heart failure.
Mosaic Gata4/6 inactivation identifies cell autonomous roles
Organ-wide cardiomyocyte gene inactivation causes both primary changes directly resulting
from gene inactivation, as well as secondary changes associated with organ dysfunction. In
some cases, such as neonatal GATA4/6 knockout by AAV9:Tnnt2-Cre, death complicates
study of gene function in processes such as physiological growth. These limitations could be
overcome by mosaic gene inactivation in a fraction of cells.
We used AAV9-Tnnt2-Cre to induce mosaic inactivation of GATA4/6 in the neonatal heart.
We administered serial dilutions of AAV9:Tnnt2-Cre to P1 GATA4fl/fl::GATA6fl/fl::Rosa26mTmG/
mTmG mice and observed progressively lower frequency of recombined cells (Fig 7A and 7B).
2x109 viral genomes/g body weight (i.e., 1:50 of the standard dose) did not globally affect heart
systolic function (Fig 7C) but still yielded enough GFP+ cells for downstream analysis. We used
this dose for subsequent mosaic inactivation studies. We isolated the GFP+, RFP+, and GFP+RFP+
cardiomyocyte populations from dissociated P7 hearts (Fig 7D). qRTPCR showed that GATA4
and GATA6 were reduced by over 80% in GFP+ and GFP+RFP+ cells compared to RFP+ cells
(Fig 7E). Thus GFP marks GATA4/6 deficient cells.
Fig 6. Expression of cardiac stressmarkers after adult cardiac inactivation ofGata4 andGata6.
qRTPCR was performed on ventricular myocardial RNA. n = 6. *, P<0.05.
doi:10.1371/journal.pone.0128105.g006
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Fig 7. Mosaic inactivation ofGata4/6 in the neonatal heart. (A). Experimental timeline. (B). Titration of AAV9:Tnnt2-Cre in neonatal Rosa26mTmG mice.
GFPmarks Cre-recombined cells. The percentage of GFP+ cells is indicated. Bar = 20 μm. (C). Relationship of virus dose to ejection fraction (red, left axis)
and recombination efficiency (black, right axis). (D-E).Gata4fl/fl::Gata6fl/fl::Rosa26mTmG neonates were treated with low dose AAV9:Tnnt2-Cre.
Cardiomyocytes were purified at P7 by magnetic cell sorting, then FACS sorted (D).Gata4 andGata6 levels, measured by qRTPCR, confirmed gene
knockout in GFP+ cells (E). (F). Size of GATA4/6 knockout cardiomyocytes at P7. The cross sectional area of GFP+ (recombined) and RFP+ (non-
recombined) cardiomyocytes in P7 cryosections was compared using the Mann-Whitney test. (G-H). Size of GATA4/6 deficient cardiomyocytes in adult
mosaic knockout hearts. Representative images of cardiomyocytes dissociated from adult hearts with mosaic GATA4/6 knockout by AAV9:Tnnt-Cre
administered at P1. (G). Bar = 20 μm. Quantitation of GFP+ and GFP- cardiomyocyte size (H) showed that GFP+ cardiomyocytes were significantly smaller by
Mann-Whitney test. In F and H, black lines represent the median and 1st and 3rd quartiles.
doi:10.1371/journal.pone.0128105.g007
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Rapid systolic dysfunction following newborn cardiac GATA4/6 inactivation (Fig 3) led us
to hypothesize that GATA factors are required for neonatal cardiomyocyte maturation, a hall-
mark of which is physiological cardiomyocyte hypertrophy. To determine the cell autonomous
requirement of GATA4/6 for neonatal cardiomyocyte growth, we delivered diluted AAV9:
Tnnt2-Cre to P1 GATA4fl/fl::GATA6fl/fl::Rosa26mTmG/mTmG mice. In histological sections at
p7, cardiomyocyte cross-sectional area of knockout cardiomyocytes (GFP+) was smaller than
controls (RFP+; 0.73-fold, P<0.0001 by Mann-Whitney; Fig 7F). The mice survived to adult-
hood with normal heart function, permitting us to assess cell autonomous GATA4/6 function
for the entire period of normal physiological heart growth. Dissociation of mosaic knockout
adult hearts revealed that GATA4/6 knockout cardiomyocytes were much smaller than con-
trols (P<0.0001 by Mann-Whitney; Fig 7G and 7H). These results indicate that GATA4/6 are
required for normal postnatal heart growth.
Discussion
By inactivating Gata4 and Gata6 in cardiomyocytes specifically in the neonatal or adult heart,
we uncovered novel stage-specific roles of these genes. Acute loss of Gata4 and Gata6 in the
perinatal period caused rapid loss of systolic function. This is a critical period in heart develop-
ment, during which time cardiomyocytes adapt to substantially higher hemodynamic demands
by undergoing numerous changes in their size, ultrastructure, sarcomere composition, and me-
tabolism. Lack of cardiomyocyte maturation is currently a major bottleneck to using repro-
grammed or stem cell-derived cardiomyocytes for cardiac repair and regeneneration [25]. Our
data show that perinatal cardiomyocyte inactivation of Gata4/6 dramatically impaired neonatal
systolic function, and mosaic inactivation of these genes revealed their essential roles in physio-
logical postnatal cardiomyocyte growth. Together, these data indicate that Gata4/6 are key reg-
ulators of postnatal cardiomyocyte maturation. Further mechanistic studies of this knockout
model will illuminate critical steps in the maturation process and its regulation by Gata4 and
Gata6.
Inactivation of Gata4 and Gata6 in adult cardiomyocytes uncovered an unexpected require-
ment of these genes to regulate mature heart diastolic function. This diagnosis was supported
by signs of severe heart failure in the face of only mild systolic dysfunction, by atrial dilatation
out of proportion to ventricular dilatation, and by echocardiographic and invasive hemody-
namic measures of diastolic function. Diastolic heart failure is a significant cause of heart fail-
ure in adult patients [26], but far less is known about the factors that govern diastolic heart
function than systolic heart function. The adult Gata4/6 knockout mouse will provide a fruitful
model to investigate the pathophysiology of diastolic heart failure.
Combined inactivation of Gata4 and Gata6 by Myh7-Cre in fetal development was reported
previously [4]. Fetal knockout of these genes was compatible with postnatal survival for up to
100 days. Surprisingly, our work shows that acute neonatal knockout was quite different and
resulted in death within 7 days. The difference between chronic and acute loss of function may
be due to secondary, compensatory adaptations that occur in the chronic model. We hypothe-
size that such compensatory changes masked the essential role of Gata4 and Gata6 in neonatal
cardiomyocyte maturation and in maintenance of normal adult heart diastolic function. Simi-
lar compensatory changes have likewise been proposed to account for differences between
acute miRNA silencing with antagomirs, compared to their chronic silencing in genetic models
[27].
The Gata4fl/fl::Gata6fl/fl::Myh7-Cre mouse model was interpreted to show an essential role
of these transcription factors in regulating adult heart systolic function; however, our data on
inactivation of these genes in the adult heart suggest that the systolic heart failure phenotype
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was a result of abnormal heart development in the absence of these key transcriptional regula-
tors. Moreover, this developmental phenotype masked a bone fide function of GATA4/6 in the
adult heart, the regulation of adult heart diastolic function. These results point out the critical
importance of regulating the timing of gene inactivation to gain insights into gene function
most relevant to the question under investigation. It is likely that many other genes that have
been studied in the adult heart following inactivation by developmentally active Cre, such as
Myh6-Cre or Myh7-Cre, should be reassessed by temporally controlled gene inactivation in
the adult heart.
The stage-specific functions of Gata4/6 in fetal, newborn, and adult stages likely reflect their
regulation of stage-specific gene programs. Consistent with this, we recently demonstrated that
GATA4 genome occupancy is highly dynamic, with most GATA4 binding sites changing be-
tween the fetal and adult heart [28]. Combining stage-specific gene inactivation and differential
expression analysis with stage-specific GATA4/6 chromatin occupancy maps will be pivotal to
elucidate the mechanistic basis for the unique requirement for GATA4/6 in fetal, newborn, and
adult heart.
Our studies demonstrate that AAV9:Tnnt2-Cre is a valuable reagent for ablation of floxed
genes in cardiomyocytes. AAV9-mediated delivery of Cre recombinase is a highly efficient,
cost-effective, and simple method to control the timing and extent of cardiomyocyte-restricted
gene knockout. The use of an independently developed AAV9:Tnnt2-Cre for cardiac gene in-
activation was recently reported [29]. In this study, the authors demonstrated that AAV9:
Tnnt2-Cre efficiently ablated floxed Srf in the adult heart. Our study further develops this idea
by showing the effectiveness of AAV9:Tnnt2-Cre for neonatal cardiomyocyte gene inactivation
and by showing how the temporal control of gene inactivation is critical for interpretation of
gene function. Furthermore, by demonstrating how reduced dosage of AAV9:Tnnt2-Cre per-
mits creation of genetic mosaics, which provide critical information about cell autonomous
gene function. We also provide addition data from closed chest catheterization showing that
AAV9-mediated Cre delivery to the heart has minimal effect on cardiac hemodynamic
parameters.
Postnatal gene inactivation with AAV9:Tnnt2-Cre has several significant strengths: (1)
AAV9:Tnnt2-Cre is highly portable between mouse lines and research institutions. This signif-
icantly reduces time and expense for experiments. (2) The timing of gene inactivation can be
precisely controlled. As shown in this study, the timing of gene inactivation can dramatically
alter the interpretation of experimental results and their interpretation, suggesting that inacti-
vating the gene of interest at the appropriate developmental stage is critically important. Cur-
rently, the most common method for inducible, adult-stage gene inactivation is
Myh6-MerCreMer [7]. However, the efficiency of gene inactivation with this reagent is vari-
able. Furthermore, the combination of the MerCreMer fusion protein and tamoxifen triggers
fibrosis and ventricular dysfunction, which can confound interpretation of experimental results
[9,10,30]. AAV9:Tnnt2-Cre offers an orthogonal, temporally controlled approach, and use of
both strategies could help to exclude technical issues related to either experimental strategy
alone. (3) AAV9:Tnnt2-Cre dose is easily titrated to achieve mosaic cardiomyocyte knockout.
As demonstrated in this study, a mosaic approach opens up new experimental opportunities
and also avoids non-cell autonomous, indirect consequences of gene knockout. Mosaic knock-
out by limited AAV9:Tnnt2-Cre differs from limiting tamoxifen administration to Myh6-Mer-
CreMer, in that in the former each transduced cell expresses robust Cre activity, whereas in the
latter many cells possess marginal Cre activity. As a result, we observed high concordance be-
tween recombination of 2 Gata4 alleles, 2 Gata6 alleles, and the Cre-activated reporter.
Proper controls are needed to most accurately interpret gene inactivation experiments with
AAV-Tnnt2-Cre. AAV-induced inflammatory responses are minimal in rodents [12], but still
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should be excluded as the cause for observed cardiac abnormalities through the use of control
AAV (e.g. AAV-luciferase). Treatment of control genotypes with AAV-Tnnt2-Cre further re-
duces the likelihood of Cre toxicity [31] or potential AAV-triggered host responses. The poten-
tial for Cre toxicity increases with long term experiments, and a desirable further refinement
would be to develop self-inactivating AAV-Cre to reduce the risk of chronic Cre exposure.
In conclusion, the interpretation of genetic knockout experiments hinges on the timing and
extent of gene inactivation. AAV9-mediated Cre delivery is a convenient tool to precisely con-
trol these critical experimental parameters for cardiac loss of function studies. Using the
strengths of the AAV9:Tnnt2-Cre platform, we defined novel roles of GATA4/6 to regulate
cardiomyocyte maturation in the newborn heart, and to maintain diastolic function in the
adult heart.
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